t
hVIVO plc confirmed that its Annual Report and Accounts for the year ended 31 December 2025 and the Notice of Annual General Meeting (AGM) would be posted to shareholders on 17 April 2026. The Annual General Meeting is scheduled to be held on 13 May 2026 at 11:00 am BST.
| Date | 17 Apr 2026 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 8284A |
hVIVO plc
("hVIVO", the "Company" or the "Group")
Annual Report & Notice of AGM
London, UK - 17 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, confirms that the Company's Annual Report and Accounts for the year ended 31 December 2025 and the Notice of Annual General Meeting ("AGM") will be posted to shareholders today.
The 2025 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website: www.hvivo.com.
The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 13 May 2026 at 11.00am BST.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |
|
|||
|
|
|
|||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 |
|||
|
Geoff Nash, Callum Davidson Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales |
|
|||
|
|
|
|||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr Christopher Golden |
|
|||
|
|
|
|||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
Anthony Farrell, Niall Gilchrist |
|
|||
|
|
|
|||
|
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
|
||||
Notes to Editors
hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.
The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.
With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.
· Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
· Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.
· Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.
· Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.